Breaking News, Collaborations & Alliances

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA

For EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Samsung Biologics has announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy.   In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal antibody provided by Eutilex. Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters